AbbVie Inc.
COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR
Last updated:
Abstract:
The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
Status:
Application
Type:
Utility
Filling date:
30 Mar 2022
Issue date:
25 Aug 2022